Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Margin data on file, last reported at 77.94% in Q1 2026.

• On a quarterly basis, Gross Margin fell 120.0% year-over-year to 77.94% in Q1 2026; TTM through Mar 2026 was 83.52%, a 149.0% decrease from a year earlier, with the FY2025 full-year figure at 83.8%, down 245.0% from the prior year.
• Gross Margin for Q1 2026 stood at 77.94%, down from 85.84% in the prior quarter.
• Over the last five years, Gross Margin for RARE reached as high as 94.85% in Q4 2022 and fell as low as 77.94% in Q1 2026.
• Historically, Gross Margin has averaged 87.18% across 5 years, with a median of 87.8% in 2023.
• Across the five-year window, Gross Margin plunged 565 bps in 2022 and soared 66 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 94.85% in 2022, then slipped by 4 bps to 90.69% in 2023, then fell by 1 bps to 89.57% in 2024, then slipped by 4 bps to 85.84% in 2025, then slipped by 9 bps to 77.94% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 77.94% in Q1 2026, 85.84% in Q4 2025, and 82.5% in Q3 2025.